What Kither Biotech does

Kither Biotech S.r.l. is a clinical-stage biopharmaceutical company founded as a spin-off from the University of Turin, Italy, developing inhaled cell-permeable peptide and small-molecule therapies for chronic respiratory diseases with high unmet medical need. The company's lead asset, KIT2014, is a 42-amino acid cell-permeable peptide that modulates intracellular cAMP signaling through upstream disruption of the PI3Kγ-PKA-PDE3/4 complex, enabling compartmentalized dual PDE3/4 inhibition across multiple airway cell types. This mechanism produces bronchodilation, anti-inflammatory effects, enhanced mucociliary clearance, improved CFTR gating, and slowing of fibrotic progression, all delivered directly to the lungs via inhalation to minimize systemic exposure. KIT2014 is being developed for COPD (lead indication), cystic fibrosis, non-CF bronchiectasis, and idiopathic pulmonary fibrosis; it has received European Medicines Agency Orphan Drug Designation for cystic fibrosis and is protected by a family of international patents. The pipeline also includes KITCL27, a small-molecule pan-PI3K inhibitor prodrug activated only inside target cells, being developed for idiopathic pulmonary fibrosis.

Name

Kither Biotech

Legal name

Kither Biotech S.r.l.

Website

https://kitherbiotech.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Kither Biotech is a clinical-stage Italian biopharmaceutical company developing inhaled cell-permeable peptide and PI3K prodrug therapies targeting chronic respiratory diseases including COPD, cystic fibrosis, non-CF bronchiectasis, and idiopathic pulmonary fibrosis.

Ownership category

akta.pro rank

Product category

Respiratory Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

Keywords

• Inhaled peptide therapeutics
• Respiratory disease drugs
• Biopharmaceutical development
• COPD therapeutics
• Cystic fibrosis treatments

Headquarters

HQ city

Torino

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: As a clinical-stage biopharmaceutical company, Kither Biotech's primary anticipated revenue stream will come from sales of approved therapeutics. The company is developing KIT2014 for multiple respiratory indications (COPD, NCFBE, CF, IPF) and KITCL27 for IPF. Following regulatory approval, the company would commercialize these products either directly or through licensing/partnership agreements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Kither Biotech develops inhaled peptide and small-molecule therapeutics targeting the PI3K signaling axis to treat chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (lead indication), Cystic Fibrosis, Non-CF Bronchiectasis and Idiopathic Pulmonary Fibrosis. Its lead asset, KIT2014, is an inhaled cell-permeable peptide modulating intracellular cAMP signaling via dual PDE3/4 inhibition, currently advancing through Phase 2 clinical development after a successful Phase 1 trial in 2025. The secondary asset, KITCL27, is a small-molecule PI3K inhibitor prodrug in development for Idiopathic Pulmonary Fibrosis.

Product overview

Kither Biotech is a clinical-stage biopharmaceutical company developing a differentiated pipeline of inhaled therapies for respiratory diseases. The company's core product is KIT2014, an innovative 42-amino acid inhaled peptide that modulates cAMP signaling through dual PDE3/4 inhibition for the treatment of COPD, cystic fibrosis, non-CF bronchiectasis, and IPF. The pipeline also includes KITCL27, a small molecule PI3K inhibitor prodrug for pulmonary fibrosis. Both products leverage localized pulmonary delivery to maximize therapeutic effects while minimizing systemic exposure.

Differentiator

Problem solved

Functional benefit

Products and services

• KIT2014 Novel inhaled 42-amino acid cell-permeable peptide that modulates intracellular cAMP signaling through upstream disruption of the PI3Kγ-PKA-PDE3/4 complex, providing combined bronchodilation, anti-inflammatory effects, mucociliary clearance enhancement, CFTR gating improvement and slowing of fibrotic progression. In clinical development for Chronic Obstructive Pulmonary Disease (lead indication), Cystic Fibrosis, Non-CF Bronchiectasis and Idiopathic Pulmonary Fibrosis. Holds EMA Orphan Drug Designation for cystic fibrosis.
• KITCL27 Small-molecule pan-PI3K inhibitor designed as an inhalation prodrug that is activated only inside target cells, blocking the enzymatic function of all PI3K family members while restricting anti-PI3K activity to the lungs and minimizing systemic toxicity (e.g., blood glucose alterations). In development for Idiopathic Pulmonary Fibrosis as monotherapy.

Quantifiable outcome

• Phase 1 clinical trial demonstrated KIT2014 was safe and well tolerated across all dose levels (0.1mg to 2mg daily for up to 7 days) with no measurable systemic exposure
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Pantherna Therapeutics GmbHcoreTechnology or Integration · 8 January 2026Kither Biotech and Pantherna Therapeutics announced a strategic research collaboration combining Pantherna's proprietary lipid nanoparticle (LNP) mRNA delivery platform with Kither's clinical-stage peptide therapeutic KIT2014. The partnership explores synergistic therapeutic approaches where mRNA-based protein restoration and peptide-driven functional enhancement work in concert to address genetic respiratory diseases. The dual-mechanism strategy pairs mRNA-based protein restoration with peptide therapy's compartmentalized cAMP signaling through PTXmRNA® and PTXΔLNP® platforms. Both companies noted the complementary nature of their platforms and indicated the collaboration opens strategic opportunities for standalone and combination development programs.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Verona Pharma: Clinical-stage company that developed ensifentrine, an inhaled dual PDE3/4 inhibitor for COPD — the same upstream signaling family targeted by KIT2014. Acquired by Merck for ~$10bn in 2024, validating both the inhaled PDE3/4 mechanism and the respiratory biotech exit pathway.
• Enterprise Therapeutics: UK-based clinical-stage biotech developing inhaled therapies for cystic fibrosis, COPD, and other respiratory diseases. Directly comparable to Kither in modality (inhaled), indication focus (CF/COPD), and development stage, though targeting ion channel and ENaC mechanisms rather than PI3Kγ.

Broad incumbents

• Chiesi Farmaceutici: Italian-headquartered global pharmaceutical company with a major respiratory franchise (Trixeo/Trimbow, Foster) covering COPD and asthma. Direct domestic peer for Kither and a likely potential acquirer or licensing partner for KIT2014 given overlapping therapeutic focus.
• Zambon: Italian pharmaceutical company with a dedicated respiratory business unit (Zambon SpA and Zambon Biotech) including products for COPD and CF. Comparable Italian-headquartered competitor with overlapping respiratory focus and potential partnership interest.
• Insmed: US biopharmaceutical company specializing in inhaled therapies for serious lung diseases (liposomal amikacin for NTM lung infection, brensocatib for bronchiectasis). Comparable specialty respiratory biotech with inhaled delivery platform and Phase 3 assets in NCFB-adjacent populations.
• AbbVie (Allergan respiratory portfolio): Global pharmaceutical company with a respiratory franchise from the Allergan acquisition, including therapies for COPD and rare pulmonary diseases. Major potential acquirer or licensing partner for clinical-stage respiratory assets with novel mechanisms.

Emerging players

• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with respiratory disease programs using targeted RNA delivery platforms. Comparable in modality innovation (delivery platform + therapeutic payload) and in targeting chronic respiratory conditions where Kither is positioned.

Others

• Translate Bio (Sanofi): Acquired by Sanofi in 2021, develops mRNA therapeutics for cystic fibrosis (CFTR mRNA delivery to lungs). Directly relevant via the Pantherna collaboration — Translate Bio is the precedent for mRNA-based CF therapeutics and a potential competitor or partner in the genetic respiratory space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCOdEyKuDWVQS56QjAfZpXzQ/featured
• LinkedInlinkedin.com/company/kither-biotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kither Biotech